Keyword: Tecentriq

Roche is looking to snag a $1 billion piece of the lung cancer market for its own, and it now has survival data to back up its bid.

Roche has been chomping at the bit to challenge Merck in previously untreated lung cancer, but it’s going to have to wait a little longer.

Excluding ALK and EGFR, about two-thirds of new NSCLC patients are now starting their treatment with Keytruda, said an executive.

Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.

Roche in July boosted the prices of nine medicines by an average of about 3%, including blockbuster oncology drugs Herceptin, Avastin and Rituxan.

Roche touted another win Thursday for Tecentriq. But the way some analysts see things, it may actually be a win for Merck's Keytruda

Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug picked up an FDA breakthrough designation in liver cancer.

All eyes have been on the I-O battle over lung cancer. But with its latest data, breast cancer leader Roche is bringing the fight to its home turf.

So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.

The FDA has warned that drugs from Merck and Roche might be hurting some bladder cancer patients’ survival chances. Now, it’s narrowed their labels.